AstraZeneca approaches Gilead about potential merger
Posted by
www.biotecnika.org
AstraZeneca, valued at $140 billion, is the U.K.'s biggest drugmaker
by market capitalization and has developed treatments for conditions
from cancer to cardiovascular disease. Gilead, worth $96 billion at
Friday's close, is the creator of a drug that's received U.S. approval
for use with coronavirus patients.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/astrazeneca-approaches-gilead-about-potential-merger/articleshow/76243855.cms
Subscribe to:
Post Comments (Atom)
Post a Comment